Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | CTSG | P08311 | 2/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.40 |
| ▸ | CMA1 | P23946 | 2/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8582147 | 0.78 | PTPN1 (0.39) | KMT2AALDH1A1MAPTLMNAL3MBTL1 | |
| SCHEMBL2406523 | 0.75 | KIF11 (0.39) | KMT2ACA2KCNN4ALDH1A1MAPT | |
| SCHEMBL4443636 | 0.74 | AVPR2 (0.44) | PTGDR2ALDH1A1MAPTNPC1SMN1; SMN2 | |
| SCHEMBL28772995 | 0.73 | KCNN4 (0.44) | KMT2ACA2KCNN4ALDH1A1MAPT | |
| SCHEMBL27653343 | 0.71 | GSK3B (0.48) | PRSS1 | |
| SCHEMBL2406465 | 0.71 | KCNN4 (0.42) | KMT2ACA2KCNN4ALDH1A1MAPT | |
| SCHEMBL3396959 | 0.70 | LMNA (0.54) | KMT2AKCNN4ALDH1A1MAPTLMNA | |
| SCHEMBL4955482 | 0.70 | KCNN4 (0.45) | KMT2ACA2KCNN4ALDH1A1MAPT | |
| SCHEMBL13940377 | 0.69 | PBRM1 (0.39) | KCNN4ALDH1A1MAPTLMNAL3MBTL1 | |
| SCHEMBL2671976 | 0.68 | CA1 (0.50) | KMT2ACA1CA2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215116-B1 | A HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | UNIV OF THE SCIENCES IN PHILADELPHIA (US) | 2020-09-30 | — | — | EP | disclosed |
| US-10265413-B2 | High molecular weight biodegradable gelatin-doxorubicin conjugate | UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 2019-04-23 | — | — | US | disclosed |
| US-10005816-B2 | Peptides and their use in food and beverage | The Folger Coffee Company (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170354741-A1 | HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 2017-12-14 | — | — | US | disclosed |
| EP-3215116-A1 | A HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | University of the Sciences in Philadelphia (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-2205624-B1 | INSULINOTROPIC PEPTIDE SYNTHESIS USING SOLID AND SOLUTION PHASE COMBINATION TECHNIQUES | CORDEN PHARMA COLORADO INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20160165916-A1 | NOVEL PEPTIDES AND THEIR USE IN FOOD AND BEVERAGE | The Folger Coffee Company | 2016-06-16 | — | — | US | disclosed |
| WO-2016077083-A1 | A HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016070241-A1 | TRIAZINE COMPOUNDS, COMPOSITIONS AND SYNTHESIS | CTXT PTY LTD (AU) | 2016-05-12 | — | — | WO | disclosed |
| US-20140343227-A1 | Diketopiperazine Forming Dipeptidyl Linker | LONZA AG (CH) | 2014-11-20 | — | — | US | disclosed |
| US-20080004429-A1 | Insulinotropic peptide synthesis using solid and solution phase combination techniques | ROCHE PALO ALTO LLC | 2008-01-03 | — | — | US | disclosed |
| WO-2007147816-A1 | INSULINOTROPIC PEPTIDE SYNTHESIS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| EP-1856142-A1 | SYNTHESIS OF PEPTIDE T-1249 USING PEPTIDE INTERMEDIATE FRAGMENTS | F. Hoffmann-Roche AG (CH) | 2007-11-21 | — | — | EP | disclosed |
| EP-1833843-A1 | SYNTHESIS OF PEPTIDE T-20 USING PEPTIDE INTERMEDIATE FRAGMENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-19 | — | — | EP | disclosed |
| US-20070213504-A1 | Synthesis using peptide intermediate fragments | ROCHE COLORADO CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20060276624-A1 | Synthesis using peptide intermediate fragments | ROCHE COLORADO CORPORATION | 2006-12-07 | — | — | US | disclosed |
| US-20060173163-A1 | Synthesis using peptide intermediate fragments | ROCHE COLORADO CORPORATION | 2006-08-03 | — | — | US | disclosed |
| WO-2006069729-A1 | SYNTHESIS OF PEPTIDE T-1249 USING PEPTIDE INTERMEDIATE FRAGMENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006069727-A2 | SYNTHESIS OF PEPTIDE T-20 USING PEPTIDE INTERMEDIATE FRAGMENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006069728-A1 | SYNTHESIS OF PEPTIDE T-20 USING PEPTIDE INTERMEDIATE FRAGMENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170354741-A1 | HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | MMP2, DNASE1L3, DNASE1 | KMT2A 4101/4885PRSS1 2003/4885CTSG 103/4885 |
| US-10265413-B2 | High molecular weight biodegradable gelatin-doxorubicin conjugate | MMP2, DNASE1L3, DNASE1 | KMT2A 4101/4885PRSS1 2003/4885CTSG 103/4885 |
| US-20080004429-A1 | Insulinotropic peptide synthesis using solid and solution phase combination techniques | IAPP, GLP1R, GIPR | KMT2A 3717/4885PRSS1 111/4885CTSG 1855/4885 |
| US-20140343227-A1 | Diketopiperazine Forming Dipeptidyl Linker | FAP, IAPP, DNPEP | KMT2A 3641/4885PRSS1 47/4885CTSG 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.